Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

BACKGROUND This report and a companion report describe a validation of the ability of serum proteomic profiling via SELDI-TOF mass spectrometry to detect prostatic cancer. Details of this 3-stage process have been described. This report describes the development of the algorithm and results of the blinded test for stage 1. METHODS We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220). We also derived a validation test set from a separate, geographically diverse set of serum samples from 42 prostate cancer patients and 42 controls without prostate cancer. Aliquots were subjected to randomization and blinded analysis, and data from each laboratory site were subjected to the decision algorithm and decoded. RESULTS Using the data collected from the validation test set, the decision algorithm was unsuccessful in separating cancer from controls with any predictive utility. Analysis of the experimental data revealed potential sources of bias. CONCLUSION The ability of the decision algorithm to successfully differentiate between prostate cancer, BPH, and control samples using data derived from serum protein profiling was compromised by bias.

[1]  Zhiyuan Luo,et al.  Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. , 2007, Clinical chemistry.

[2]  M. Girolami,et al.  Clinical proteomics: A need to define the field and to begin to set adequate standards , 2007, Proteomics. Clinical applications.

[3]  Paul J Utz,et al.  Technology Insight: can autoantibody profiling improve clinical practice? , 2007, Nature Clinical Practice Rheumatology.

[4]  E. Diamandis.  Peptidomics for cancer diagnosis: present and future. , 2006, Journal of proteome research.

[5]  D. Chan,et al.  Proteomics: a new diagnostic frontier. , 2006, Clinical chemistry.

[6]  T W Randolph,et al.  Multiscale Processing of Mass Spectrometry Data , 2006, Biometrics.

[7]  Sen-Yung Hsieh,et al.  Systematical evaluation of the effects of sample collection procedures on low‐molecular‐weight serum/plasma proteome profiling , 2006, Proteomics.

[8]  E. Diamandis.  Validation of breast cancer biomarkers identified by mass spectrometry. , 2006, Clinical chemistry.

[9]  T. Libermann,et al.  SELDI‐TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions , 2006, Proteomics.

[10]  J. Barrett,et al.  Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. , 2005, Clinical chemistry.

[11]  E. Marchiori,et al.  Sample handling for mass spectrometric proteomic investigations of human sera. , 2005, Analytical chemistry.

[12]  Graham B. I. Scott,et al.  HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples , 2005, Proteomics.

[13]  T. Veenstra,et al.  Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. , 2005, Clinical chemistry.

[14]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[15]  Upender Manne,et al.  The Need for Review and Understanding of SELDI/MALDI Mass Spectroscopy Data Prior to Analysis , 2005, Cancer informatics.

[16]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[17]  G. Hortin,et al.  Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. , 2004, Clinical chemistry.

[18]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[19]  Jeffrey S. Morris,et al.  Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..

[20]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[21]  D. McCarthy,et al.  Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer , 2004, Disease markers.

[22]  Y. Yasui,et al.  An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers , 2003, Journal of biomedicine & biotechnology.

[23]  A. Vlahou,et al.  A novel approach toward development of a rapid blood test for breast cancer. , 2003, Clinical breast cancer.

[24]  Min Zhan,et al.  A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.

[25]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[26]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[27]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[28]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[29]  K. Lillemoe,et al.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.

[30]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[31]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[32]  B. Korf,et al.  Molecular diagnosis (2) , 1995, The New England journal of medicine.